3m Littman stethoscope is without doubt one of the crucial medical equipments that health-related practitioner are making use of in their clinics. There are actually distinct different types of these stethoscopes which makes it effortless for your clinical practitioner to get the perfect a single for his line of health-related subject. Health-related industry experts depend on this sort of stethoscopes and this is because of their first-class acoustics, dependable operation and unsurpassed top quality and provider.
Each time a health-related practitioner is attending to his patient, he must make certain that he is working with superior stethoscope as this is actually the only way that he’ll have the ability to acquire accurate effects. Getting exact results allows a single in order to give the correct analysis. There are several attributes that make 3m Littman stethoscope a stethoscope that is certainly favored by a lot of clinical practitioners.
When a clinical practitioner is employing 3m Littman stethoscope, he’s guaranteed that he’ll be able to offer the ideal analysis. It is because this kind of stethoscope includes a superior acoustic that allows the practitioner employing it to have the ability to listen to even the faintest audio being produced by his patients’ organs. For a healthcare practitioner to create sure the 3m Littman stethoscope that he’s employing is going to be in a position to offer him exact outcomes, he ought to be sure that he is using a top quality one.
There are various resources that a healthcare practitioner can use to receive a stethoscope that could be effective into his line of health-related subject. Amid the most beneficial supply that a clinical practitioner can use to glimpse for his ideal kind of stethoscope is on-line. World wide web has made it effortless for people to perform their shopping when you may get virtually every little thing on the internet. Trying to find 3m Littman stethoscope on line is easy as all th! at you&# 8217;re supposed to acquire is often a laptop linked to a efficient internet.
Searching on the net permits a person to avoid wasting time as he’ll not need to go from just one healthcare furnish shop to your other looking for the correct form of stethoscope. All that a medical practitioner could have to carry out would be to kind the identify and have the opportunity to look at the different kinds and versions which have been out there.
3m Littman stethoscopeAll that a healthcare practitioner will have to complete is to style the name and find a way to look at the different varieties and versions which can be readily available.
Showing posts with label Gold Stocks. Show all posts
Showing posts with label Gold Stocks. Show all posts
Saturday, February 25, 2012
Tuesday, February 14, 2012
'How to Be A Gentleman' Nears Cancellation
It looks like CBS'(CBS) new comedy How to be a Gentleman could be next on the list of cancelled shows.
According to reports, the network shut down production of the series, which stars Kevin Dillon and was created by David Hornsby. The remaining seven episodes will air on Saturday nights.
How to be a Gentleman premiered to mediocre ratings, and its second episode saw a 7% decline in viewers between 18 and 49 years old. If CBS pulls the plug on How to be a Gentleman, it will join The Playboy Club, Free Agents and H8R, which all were cancelled last week.
-Reported by Jeanine Poggi in New York.
Follow TheStreet.com on Twitter and become a fan on Facebook.
>To order reprints of this article, click here: Reprints
According to reports, the network shut down production of the series, which stars Kevin Dillon and was created by David Hornsby. The remaining seven episodes will air on Saturday nights.
How to be a Gentleman premiered to mediocre ratings, and its second episode saw a 7% decline in viewers between 18 and 49 years old. If CBS pulls the plug on How to be a Gentleman, it will join The Playboy Club, Free Agents and H8R, which all were cancelled last week.
-Reported by Jeanine Poggi in New York.
Follow TheStreet.com on Twitter and become a fan on Facebook.
>To order reprints of this article, click here: Reprints
Thursday, January 26, 2012
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs
Amgen? (Nasdaq: AMGN ) has spent years defending itself from enemies in the generic drug business, but now the world's largest biotech company has found a way to join forces with a major maker of copycat pharmaceuticals.
Thousand Oaks, CA-based Amgen, which has R&D operations in Seattle, San Francisco, and Boston, said today it has agreed to collaborate with Parsippany, NJ-based Watson Pharmaceuticals (NYSE: WPI ) to develop and sell targeted antibody drugs for cancer that are "biosimilar" knock-offs of the originals. Watson has agreed to pump as much as $400 million into developing the molecules, while Amgen will contribute its specialized expertise and infrastructure for producing these complex protein drugs that are made in living cells.
The companies didn't say in today's joint statement which cancer antibody drugs they will attempt to make as biosimilars. But the companies did say that the partnership will not make lower-cost versions of Amgen's billion-dollar biotech drugs like etanercept (Enbrel) or epoetin alfa and darbepoetin alfa (Epogen and Aranesp). The biosimilar drugs will be sold under a joint Amgen/Watson label, and Watson will receive royalties and sales milestones from product revenues.
Major biotech companies, like Amgen and Genentech, have argued for years that biologic drugs like theirs can't be copied in the same straightforward manner as conventional small-molecule chemical compounds like those made by traditional drug companies like Pfizer and Merck. Since biotech drugs are incubated inside living cells that are maintained in carefully controlled bioreactors, much of what makes the product unique is the trade-secret protected manufacturing process that isn't part of the patent that covers the molecule itself. Tiny alterations to this process can lead to fundamental changes in the product itself, which the big ! companie s have argued requires new clinical trials for "biosimilar" products.
Generic companies have countered that new clinical trials would add too much time and expense to the development process, making it impossible for their biosimiliar products to be offered as cheaply and easily as a new generic version of, say, Pfizer's atorvastatin (Lipitor). The new business model hasn't really been established yet in the U.S., but other major drug companies, including Merck, have shown interest in biosimilar drugs that presumably would be cheaper than brand-name originals, but more expensive, and more profitable, than conventional generic pills. More recently, Biogen Idec and Samsung have agreed to collaborate on making biosimilar drugs.
"This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients," Amgen and Watson said in their joint statement.
Watson is holding a live webcast to discuss the collaboration today at 5 p.m. Eastern/2 p.m. Pacific.
More from Xconomy.com:
Thousand Oaks, CA-based Amgen, which has R&D operations in Seattle, San Francisco, and Boston, said today it has agreed to collaborate with Parsippany, NJ-based Watson Pharmaceuticals (NYSE: WPI ) to develop and sell targeted antibody drugs for cancer that are "biosimilar" knock-offs of the originals. Watson has agreed to pump as much as $400 million into developing the molecules, while Amgen will contribute its specialized expertise and infrastructure for producing these complex protein drugs that are made in living cells.
The companies didn't say in today's joint statement which cancer antibody drugs they will attempt to make as biosimilars. But the companies did say that the partnership will not make lower-cost versions of Amgen's billion-dollar biotech drugs like etanercept (Enbrel) or epoetin alfa and darbepoetin alfa (Epogen and Aranesp). The biosimilar drugs will be sold under a joint Amgen/Watson label, and Watson will receive royalties and sales milestones from product revenues.
Major biotech companies, like Amgen and Genentech, have argued for years that biologic drugs like theirs can't be copied in the same straightforward manner as conventional small-molecule chemical compounds like those made by traditional drug companies like Pfizer and Merck. Since biotech drugs are incubated inside living cells that are maintained in carefully controlled bioreactors, much of what makes the product unique is the trade-secret protected manufacturing process that isn't part of the patent that covers the molecule itself. Tiny alterations to this process can lead to fundamental changes in the product itself, which the big ! companie s have argued requires new clinical trials for "biosimilar" products.
Generic companies have countered that new clinical trials would add too much time and expense to the development process, making it impossible for their biosimiliar products to be offered as cheaply and easily as a new generic version of, say, Pfizer's atorvastatin (Lipitor). The new business model hasn't really been established yet in the U.S., but other major drug companies, including Merck, have shown interest in biosimilar drugs that presumably would be cheaper than brand-name originals, but more expensive, and more profitable, than conventional generic pills. More recently, Biogen Idec and Samsung have agreed to collaborate on making biosimilar drugs.
"This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients," Amgen and Watson said in their joint statement.
Watson is holding a live webcast to discuss the collaboration today at 5 p.m. Eastern/2 p.m. Pacific.
More from Xconomy.com:
- Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom
- Itero, Seeking a "Biosimilar" That's Better, Strikes Deal With Watson for Female Infertility
- Amgen's Dmab Cuts Fracture Risk for Osteoporosis Patients, Just What Investors Wanted to See
Saturday, November 12, 2011
Top Oil Stocks 2011/2012 – Top Oil Stocks to Buy 2011/2012
Oil Stocks to Buy 2011/2012- 2011/2012 Oil Stocks
Below is a list of my latest oil stock picks for 2011/2012. These 2011/2012 Oil Stock Picks are my favor stocks to buy and some of the stocks I will be trading personally. Last year, one of my top oil stock picks was Brigham Exploration (BEXP). BEXP stock went from $15 to $27 from July to December of 2010 and was one of my biggest stock gainers of the year. I feel 2011 will be a good year for stocks and the overall stock market. Oil in 2011 should hit $110-$120 which would make the oil stocks rally even higher.
Key Areas of Oil Exploration in 2011 – Eagle Ford Shale – Niobrara Shale – Bakken Shale – Permian Basin – Oil Discoveries are still going on in these fields and in 2011, more Oil Discoveries will be made. Keep an eye on the Chainman Shale – Cabot Oil & Gas (COG) mentioned in late 2010 that they are drilling for oil in the Chainman Shale. We also have Venoco (VQ) drilling the Monterey Shale in California. With that, here is a list of my best oil stock picks for 2011
#1 Top Oil Stock Pick 2011/2012 – Oil Stocks – Hyperdynamics Corporation (HDY) – While Hyperdynamics (HDY) is my top stock pick of 2010, it is a risky one. The company has no revenues and does not make any money but could be sitting on a very large pool of oil off the coast of Africa. Drilling for oil is expected to begin in December 2011. Hyperdynamics was headed into a downward spiral over the past couple years but changed the management team in 2010 who vowed to take the company in a new direction. Hyperdynamics has a very large prospective leased area off the coast of the Republic of Guinea. In November 2010, Hyperdynamics raised $30 million in a private placement from financial giant Blackrock (BLK) which will help in preperation costs to drill for oil in late 2011. Hyperdynamics did a few surveys and believe they could be sitting on billions of barrels of oil.
As for HDY stock in 2011, It is my top stock to buy and my best trading idea. I have been trading HDY since the stock was $1.60 in August 2010 and gave it a price target of $4 – $6 for 2011. HDY hit a high of $3.63 in October 2010 and continues to trade around $3.00 as we head into 2011. If everything goes as planned and the company does infact sit on top of a large oil pool, we could be looking at a $8-$10 stock by year end 2011 in my opinion. I gave it a target of $4 – $6 when the stock was hitting $2.60 just to be on the conservative side. Of coarse, if Hyperdynamics announces any delays or lesser oil reserves, all bets are off. Pullbacks below $2.50 should be a great buy if you are looking for an entry point. I currently own HDY stock for the long term and will buy more stock on pullbacks. If you have any questions or feel like discussing HDY stock, visit my HDY message forum thread.
#2 Top Oil Stock Pick for 2011 - Kodiak Oil & Gas (KOG) – Kodiak Oil & Gas was another huge stock gainer for me at the end of 2010. I bought KOG stock at $4.30 in mid November 2010 and sold between $5.00-$5.70 a month later. KOG went on to hit $6.69 a few weeks later. Kodiak Oil in Gas recently aquired additional acreage in the Bakken Shale. This acreage is in some of the best zones in the Bakken which includes the Three Forks Oil zone. When I originally bought KOG at $4.30, I placed a personal target of $8-$10 on it for 2011. I am sticking with this and feel the stock could even hit $12. A lot will depend on what oil does but ultimately the stock is going a lot higher. While I don’t own KOG right now, I plan to buy the stock on any major correction.
Below is a list of my latest oil stock picks for 2011/2012. These 2011/2012 Oil Stock Picks are my favor stocks to buy and some of the stocks I will be trading personally. Last year, one of my top oil stock picks was Brigham Exploration (BEXP). BEXP stock went from $15 to $27 from July to December of 2010 and was one of my biggest stock gainers of the year. I feel 2011 will be a good year for stocks and the overall stock market. Oil in 2011 should hit $110-$120 which would make the oil stocks rally even higher.
Key Areas of Oil Exploration in 2011 – Eagle Ford Shale – Niobrara Shale – Bakken Shale – Permian Basin – Oil Discoveries are still going on in these fields and in 2011, more Oil Discoveries will be made. Keep an eye on the Chainman Shale – Cabot Oil & Gas (COG) mentioned in late 2010 that they are drilling for oil in the Chainman Shale. We also have Venoco (VQ) drilling the Monterey Shale in California. With that, here is a list of my best oil stock picks for 2011
#1 Top Oil Stock Pick 2011/2012 – Oil Stocks – Hyperdynamics Corporation (HDY) – While Hyperdynamics (HDY) is my top stock pick of 2010, it is a risky one. The company has no revenues and does not make any money but could be sitting on a very large pool of oil off the coast of Africa. Drilling for oil is expected to begin in December 2011. Hyperdynamics was headed into a downward spiral over the past couple years but changed the management team in 2010 who vowed to take the company in a new direction. Hyperdynamics has a very large prospective leased area off the coast of the Republic of Guinea. In November 2010, Hyperdynamics raised $30 million in a private placement from financial giant Blackrock (BLK) which will help in preperation costs to drill for oil in late 2011. Hyperdynamics did a few surveys and believe they could be sitting on billions of barrels of oil.
As for HDY stock in 2011, It is my top stock to buy and my best trading idea. I have been trading HDY since the stock was $1.60 in August 2010 and gave it a price target of $4 – $6 for 2011. HDY hit a high of $3.63 in October 2010 and continues to trade around $3.00 as we head into 2011. If everything goes as planned and the company does infact sit on top of a large oil pool, we could be looking at a $8-$10 stock by year end 2011 in my opinion. I gave it a target of $4 – $6 when the stock was hitting $2.60 just to be on the conservative side. Of coarse, if Hyperdynamics announces any delays or lesser oil reserves, all bets are off. Pullbacks below $2.50 should be a great buy if you are looking for an entry point. I currently own HDY stock for the long term and will buy more stock on pullbacks. If you have any questions or feel like discussing HDY stock, visit my HDY message forum thread.
#2 Top Oil Stock Pick for 2011 - Kodiak Oil & Gas (KOG) – Kodiak Oil & Gas was another huge stock gainer for me at the end of 2010. I bought KOG stock at $4.30 in mid November 2010 and sold between $5.00-$5.70 a month later. KOG went on to hit $6.69 a few weeks later. Kodiak Oil in Gas recently aquired additional acreage in the Bakken Shale. This acreage is in some of the best zones in the Bakken which includes the Three Forks Oil zone. When I originally bought KOG at $4.30, I placed a personal target of $8-$10 on it for 2011. I am sticking with this and feel the stock could even hit $12. A lot will depend on what oil does but ultimately the stock is going a lot higher. While I don’t own KOG right now, I plan to buy the stock on any major correction.
Subscribe to:
Posts (Atom)
